GlassScriptPhysician profile
Heather N Phillips
NPI 1801007596
$2,945.62
in general payments reported to CMS, 2019-2025
38 companies · $567 in 2025
The $567 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $206 · 2021: $425 · 2022: $476 · 2023: $440 · 2024: $625 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,632.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $631.86 | 2020-2025 | |
| Novo Nordisk INC | $599.29 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $185.37 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $166.11 | 2020-2025 | Airsupra |
| Amarin Pharma, INC. | $100.00 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $96.78 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.57 | 2019-2022 | |
| Astellas Pharma US INC | $88.42 | 2020-2025 | Veozah |
| Pfizer INC. | $78.12 | 2023-2025 | |
| Lundbeck LLC | $76.42 | 2022-2024 | Vyepti |
| Xeris Pharmaceuticals, INC. | $69.57 | 2023 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.42 | 2021-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $61.46 | 2020-2023 | Shingrix, Bexsero |
| Cranial Technologies, INC | $60.21 | 2023-2025 | Doc Band |
| Inspire Medical Systems, INC. | $53.82 | 2023-2024 | Inspire |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impel Pharmaceuticals LLC | $49.02 | 2025 | Trudhesa |
| Merck Sharp & Dohme LLC | $41.75 | 2020-2021 | |
| Antares Pharma, INC. | $39.59 | 2022-2024 | Xyosted |
| Novartis Pharmaceuticals Corporation | $37.31 | 2021-2022 | |
| Exact Sciences Corporation | $31.65 | 2023-2024 | Cologuard Collection Kit |
| Allergan, INC. | $31.13 | 2020 | |
| Genzyme Corporation | $28.81 | 2025 | |
| Vistapharm, INC. | $25.83 | 2021 | |
| Ironshore Pharmaceuticals INC. | $25.33 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.79 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.40 | 2022 | |
| Verrica Pharmaceuticals INC. | $18.58 | 2024 | Ycanth |
| Vbi Vaccine (Delaware) INC. | $15.30 | 2022 | |
| Amgen INC. | $15.29 | 2021 | |
| Supernus Pharmaceuticals, INC. | $15.16 | 2025 | Qelbree |
| Sanofi Pasteur INC. | $14.66 | 2020 | |
| Esperion Therapeutics, INC. | $14.27 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.01 | 2019 | |
| Seqirus USA INC | $13.99 | 2021 | |
| Evoke Pharma, INC. | $13.62 | 2023 | Gimoti |
| Ultragenyx Pharmaceutical INC. | $13.58 | 2019 | |
| Sobi, INC | $13.24 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.